Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Cannabis Professional’s daily roundup of industry news. View archive here.

Breaking news from Tilray this morning, which is spending up to $110-million to acquire Calgary based retailer FOUR20. WeedMD posted impressive results after market on Wednesday, with sales more than doubling and significant improvements in gross margins. Emerald Health, which also reported Wednesday, showed some improvement in sales, though costs remain high. The company’s bottom line was saved by a $14.5-million contribution from its joint venture with Village Farms.

– Mark Rendell

Story continues below advertisement

Tilray to buy Alberta retail chain for up to $110-million

Tilray Inc. is getting into the retail game. On Thursday, Tilray announced that it has signed a definitive agreement to acquire Alberta-based 420 Investments Ltd., which owns six stores in Alberta and has “16 additional high-traffic store locations secured in desirable locations in Alberta, including Canmore, Calgary and Edmonton.”

The all-share acquisition will see Tilray issue $70-million worth of class 2 common stock to the owners of FOUR20. Tilray may issue a further $40-million worth of shares “subject to the achievement of certain performance milestones by FOUR20.”

The deal, which is being done through Tilray’s subsidiary of High Park Holdings Ltd, still needs approval from Canadian regulators.

- Mark Rendell

WeedMD sales surge and margins improve, with expansion of production

WeedMD Inc. saw revenues surge and gross margins increase, as the company expanded its facilities in Strathroy, Ont. and improved efficiency in the most recent quarter. WeedMD sold $8-million worth of cannabis, mostly to other licensed producers, up from $3.3-million in the preceding quarter. The gross margin on those sales increased from 15 per cent to 46 per cent, which is “mainly attributable to a significant increase in sales and a decrease in the cost of sales,” the company said.

The weighted average cost of sales per gram dropped 37 per cent to $1.84, compared with $2.90 in the previous quarter.

The company’s adjusted EBITDA loss (a non-IFRS measure) for the quarter was $662,822; the company posted a net income of $12.6-million, although that was largely to do with a change in the fair value of biological assets.

Story continues below advertisement

WeedMD focused heavily on the wholesale market in the quarter, with 72 per cent of sales going to other LPs and only 24 per cent going to provincial wholesalers who sell into the recreational retail market. Five per cent of sales were direct-to-patient medical sales.

Emerald sales up, though cost of goods sold remains high

Emerald Health reported an increase in net sales to $4.6-million, although maintained a negative gross margin, as cost of goods sold remained higher than revenues.

“The gross margin was significantly impacted by the amortization of the Health Canada license and increased production costs, as well as increased volume of purchased product sold,” the company said in its MD&A

Losses from its own operations was $13.7-million. This was offset by $14.5-million which was the company’s share of income from its joint venture with Village Farms, leading to a net loss of $452,731.

Recently, around the industry:
Conference call with James Burns
Cannabis Professional
Conference call with James Burns on the key challenges facing recreational cannabis retailers

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies